Effects of Pirfenidone and Nintedanib on Markers of Systemic Oxidative Stress and Inflammation in Patients with Idiopathic Pulmonary Fibrosis: A Preliminary Report.
Effects of Pirfenidone and Nintedanib on Markers of Systemic Oxidative Stress and Inflammation in Patients with Idiopathic Pulmonary Fibrosis: A Preliminary Report.
复制标题
吡非尼酮和尼达尼布对特发性肺纤维化患者全身氧化应激和炎症标志物的影响：初步报告。
DOI：
10.3390/antiox9111064
复制
发表时间：
2020-10-30
期刊：
影响因子：
--
通讯作者：
Zinellu A
中科院分区：
文献类型：
--
作者：
Fois AG;Sotgiu E;Scano V;Negri S;Mellino S;Zinellu E;Pirina P;Pintus G;Carru C;Mangoni AA;Zinellu A
简介：体外证据表明吡非尼酮和尼达尼布（获批用于治疗特发性肺纤维化（IPF）的药物）可发挥抗炎和抗氧化作用。我们旨在研究IPF患者体内的这种作用。研究方法：氧化应激的全身循环标志物[核因子红细胞2相关因子2（Nrf 2）、硫代巴比妥酸反应物质（TBARS）、同型半胱氨酸（Hcy）、半胱氨酸（Cys）、不对称二甲基精氨酸（ADMA）和ADMA/精氨酸比值、谷胱甘肽（GSH）、血浆蛋白-SH（PSH）和牛磺酸（Tau）]和炎症[犬尿氨酸（Kyn），在18例IPF患者（10例接受吡非尼酮治疗，8例接受尼达尼布治疗）和18例年龄和性别匹配的健康对照中，在基线和24周治疗后测量色氨酸（Trp）和Kyn/Trp比值。结果如下：与对照组相比，IPF患者的还原型血GSH（457 ± 73 µmol/L vs 880 ± 212 µmol/L，p < 0.001）和血浆PSH（4.24 ± 0.95 µmol/g prot vs 5.28 ± 1.35 µmol/g prot，p = 0.012）浓度显著降低。吡非尼酮治疗显著降低了Kyn/Trp比值（基线0.030 ± 0.011 vs治疗后0.025 ± 0.010，p = 0.048），而尼达尼布治疗显著增加了血GSH（486 ± 70 μmol/L vs 723 ± 194 μmol/L，p = 0.006）和ADMA浓度降低（0.501 ± 0.094 vs 0.468 ± 0.071 μmol/L，p = 0.024）。结论：吡非尼酮和尼达尼布对IPF患者的氧化应激和炎症特异性标志物具有有益作用。
Introduction: In vitro evidence suggests that pirfenidone and nintedanib, approved agents for the treatment of idiopathic pulmonary fibrosis (IPF), exert anti-inflammatory and anti-oxidant effects. We aimed to investigate such effects in vivo in IPF patients. Methods: Systemic circulating markers of oxidative stress [nuclear factor erythroid 2–related factor 2 (Nrf2), thiobarbituric acid- reactive substances (TBARS), homocysteine (Hcy), cysteine (Cys), asymmetric dimethylarginine (ADMA) and ADMA/Arginine ratio, glutathione (GSH), plasma protein –SH (PSH), and taurine (Tau)] and inflammation [Kynurenine (Kyn), Tryptophan (Trp) and Kyn/Trp ratio] were measured at baseline and after 24-week treatment in 18 IPF patients (10 treated with pirfenidone and 8 with nintedanib) and in 18 age- and sex-matched healthy controls. Results: Compared to controls, IPF patients had significantly lower concentrations of reduced blood GSH (457 ± 73 µmol/L vs 880 ± 212 µmol/L, p < 0.001) and plasma PSH (4.24 ± 0.95 µmol/g prot vs 5.28 ± 1.35 µmol/g prot, p = 0.012). Pirfenidone treatment significantly decreased the Kyn/Trp ratio (0.030 ± 0.011 baseline vs 0.025 ± 0.010 post-treatment, p = 0.048) whilst nintedanib treatment significantly increased blood GSH (486 ± 70 μmol/L vs 723 ± 194 μmol/L, p = 0.006) and reduced ADMA concentrations (0.501 ± 0.094 vs. 0.468 ± 0.071 μmol/L, p = 0.024). Conclusion: pirfenidone and nintedanib exert beneficial effects on specific markers of oxidative stress and inflammation in IPF patients.
登录
查看更多内容
影响因子：
24.3
作者：
Beeh, KM;Beier, J;Buhl, R
通讯作者：
Buhl, R
影响因子：
1.7
作者：
Boxhammer, Elke;Lehle, Karla;von Suesskind-Schwendi, Marietta
通讯作者：
von Suesskind-Schwendi, Marietta
影响因子：
5.8
作者：
Fois AG;Paliogiannis P;Sotgia S;Mangoni AA;Zinellu E;Pirina P;Carru C;Zinellu A
通讯作者：
Zinellu A
DOI：
10.3904/kjim.2017.030
发表时间：
2018-07
期刊：
The Korean journal of internal medicine
影响因子：
--
作者：
Ban WH;Kang HH;Kim IK;Ha JH;Joo H;Lee JM;Lim JU;Lee SH;Rhee CK
通讯作者：
Rhee CK
影响因子：
--
作者：
Kim S;Lim JH;Woo CH
通讯作者：
Woo CH